Cargando…
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic with millions infected and more than 1 million fatalities. Questions regarding the robustness, functionality, and longevity of the antibody response to the virus remain unanswered. Here, on the basis of a datas...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810037/ https://www.ncbi.nlm.nih.gov/pubmed/33115920 http://dx.doi.org/10.1126/science.abd7728 |
_version_ | 1783637240815026176 |
---|---|
author | Wajnberg, Ania Amanat, Fatima Firpo, Adolfo Altman, Deena R. Bailey, Mark J. Mansour, Mayce McMahon, Meagan Meade, Philip Mendu, Damodara Rao Muellers, Kimberly Stadlbauer, Daniel Stone, Kimberly Strohmeier, Shirin Simon, Viviana Aberg, Judith Reich, David L. Krammer, Florian Cordon-Cardo, Carlos |
author_facet | Wajnberg, Ania Amanat, Fatima Firpo, Adolfo Altman, Deena R. Bailey, Mark J. Mansour, Mayce McMahon, Meagan Meade, Philip Mendu, Damodara Rao Muellers, Kimberly Stadlbauer, Daniel Stone, Kimberly Strohmeier, Shirin Simon, Viviana Aberg, Judith Reich, David L. Krammer, Florian Cordon-Cardo, Carlos |
author_sort | Wajnberg, Ania |
collection | PubMed |
description | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic with millions infected and more than 1 million fatalities. Questions regarding the robustness, functionality, and longevity of the antibody response to the virus remain unanswered. Here, on the basis of a dataset of 30,082 individuals screened at Mount Sinai Health System in New York City, we report that the vast majority of infected individuals with mild-to-moderate COVID-19 experience robust immunoglobulin G antibody responses against the viral spike protein. We also show that titers are relatively stable for at least a period of about 5 months and that anti-spike binding titers significantly correlate with neutralization of authentic SARS-CoV-2. Our data suggest that more than 90% of seroconverters make detectable neutralizing antibody responses. These titers remain relatively stable for several months after infection. |
format | Online Article Text |
id | pubmed-7810037 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Association for the Advancement of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-78100372021-01-19 Robust neutralizing antibodies to SARS-CoV-2 infection persist for months Wajnberg, Ania Amanat, Fatima Firpo, Adolfo Altman, Deena R. Bailey, Mark J. Mansour, Mayce McMahon, Meagan Meade, Philip Mendu, Damodara Rao Muellers, Kimberly Stadlbauer, Daniel Stone, Kimberly Strohmeier, Shirin Simon, Viviana Aberg, Judith Reich, David L. Krammer, Florian Cordon-Cardo, Carlos Science Reports Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic with millions infected and more than 1 million fatalities. Questions regarding the robustness, functionality, and longevity of the antibody response to the virus remain unanswered. Here, on the basis of a dataset of 30,082 individuals screened at Mount Sinai Health System in New York City, we report that the vast majority of infected individuals with mild-to-moderate COVID-19 experience robust immunoglobulin G antibody responses against the viral spike protein. We also show that titers are relatively stable for at least a period of about 5 months and that anti-spike binding titers significantly correlate with neutralization of authentic SARS-CoV-2. Our data suggest that more than 90% of seroconverters make detectable neutralizing antibody responses. These titers remain relatively stable for several months after infection. American Association for the Advancement of Science 2020-12-04 2020-10-28 /pmc/articles/PMC7810037/ /pubmed/33115920 http://dx.doi.org/10.1126/science.abd7728 Text en Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works https://creativecommons.org/licenses/by/4.0/ https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution license (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Reports Wajnberg, Ania Amanat, Fatima Firpo, Adolfo Altman, Deena R. Bailey, Mark J. Mansour, Mayce McMahon, Meagan Meade, Philip Mendu, Damodara Rao Muellers, Kimberly Stadlbauer, Daniel Stone, Kimberly Strohmeier, Shirin Simon, Viviana Aberg, Judith Reich, David L. Krammer, Florian Cordon-Cardo, Carlos Robust neutralizing antibodies to SARS-CoV-2 infection persist for months |
title | Robust neutralizing antibodies to SARS-CoV-2 infection persist for months |
title_full | Robust neutralizing antibodies to SARS-CoV-2 infection persist for months |
title_fullStr | Robust neutralizing antibodies to SARS-CoV-2 infection persist for months |
title_full_unstemmed | Robust neutralizing antibodies to SARS-CoV-2 infection persist for months |
title_short | Robust neutralizing antibodies to SARS-CoV-2 infection persist for months |
title_sort | robust neutralizing antibodies to sars-cov-2 infection persist for months |
topic | Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810037/ https://www.ncbi.nlm.nih.gov/pubmed/33115920 http://dx.doi.org/10.1126/science.abd7728 |
work_keys_str_mv | AT wajnbergania robustneutralizingantibodiestosarscov2infectionpersistformonths AT amanatfatima robustneutralizingantibodiestosarscov2infectionpersistformonths AT firpoadolfo robustneutralizingantibodiestosarscov2infectionpersistformonths AT altmandeenar robustneutralizingantibodiestosarscov2infectionpersistformonths AT baileymarkj robustneutralizingantibodiestosarscov2infectionpersistformonths AT mansourmayce robustneutralizingantibodiestosarscov2infectionpersistformonths AT mcmahonmeagan robustneutralizingantibodiestosarscov2infectionpersistformonths AT meadephilip robustneutralizingantibodiestosarscov2infectionpersistformonths AT mendudamodararao robustneutralizingantibodiestosarscov2infectionpersistformonths AT muellerskimberly robustneutralizingantibodiestosarscov2infectionpersistformonths AT stadlbauerdaniel robustneutralizingantibodiestosarscov2infectionpersistformonths AT stonekimberly robustneutralizingantibodiestosarscov2infectionpersistformonths AT strohmeiershirin robustneutralizingantibodiestosarscov2infectionpersistformonths AT simonviviana robustneutralizingantibodiestosarscov2infectionpersistformonths AT abergjudith robustneutralizingantibodiestosarscov2infectionpersistformonths AT reichdavidl robustneutralizingantibodiestosarscov2infectionpersistformonths AT krammerflorian robustneutralizingantibodiestosarscov2infectionpersistformonths AT cordoncardocarlos robustneutralizingantibodiestosarscov2infectionpersistformonths |